Keywords: Eli Lilly, Pomaglumetad methionil, Schizophrenia, R&D charge

Lilly halts development of schizophrenia candidate pomaglumetad methionil

Article | 30 August 2012

Print This

US drug major Eli Lilly (NYSE: LLY) saw its shares dip less than 1% to $44.51 in morning trading yesterday, as the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in